Skip to content
2000
image of Safety Reporting for Auxiliary Medicinal Products in the Sibeprenlimab Phase-III Study According to the New European Union (536/2014) CT Regulation

Abstract

Introduction

The new European Union clinical trials regulation (EU CTR 536/2014) introduced the novel concept of Auxiliary Medicinal Products (AxMPs) to be implemented in clinical trials in Europe. This study aimed to understand the changes introduced under EU CTR 536/2014 with respect to AxMP requirements, implement the new regulatory mandates for AxMPs, and raise awareness among the sponsors on the collection, analysis, and reporting obligation of adverse events (AEs) to AxMPs.

Methods

Using the cross-functional approach to incorporate new methods for collecting, reporting, and assessing AEs with AxMPs, the commonly prescribed AxMPs used to treat the target indication were identified. The pharmacovigilance (PV) system [safety database] was also updated to ensure appropriate AxMP-related case processing and reporting.

Results

Based on impact assessment, PV processes related to safety data collection and submissions were updated to reflect EU CTR requirements for AxMPs. The study documents were updated to comply with AxMP-related regulatory obligations. World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) code level 3 was used to classify relevant AxMPs. Study drug configurations and user-defined field customizations were made to the safety database.

Discussion

Otsuka submitted a Clinical Trial Application (CTA) under EU CTR for one of the ongoing clinical trials. This manuscript discusses an approach to meet the regulatory mandates for safety reporting requirements of AxMPs and provides an opportunity to implement learnings from the extensive gap analysis to internal systems and processes.

Conclusion

From the gap analysis and impact assessment of EU CTR, appropriate changes were made to the existing PV processes, study-specific documents, and the safety database to ensure compliance with the EU CTR.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863329287250411114336
2025-04-29
2025-10-28

  • From This Site

    /content/journals/cds/10.2174/0115748863329287250411114336
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Gehring M. Taylor R.S. Mellody M. Casteels B. Piazzi A. Gensini G. Ambrosio G. Factors influencing clinical trial site selection in Europe: The survey of attitudes towards trial sites in europe (the sat-eu study). BMJ Open 2013 3 11 e002957 10.1136/bmjopen‑2013‑002957 24240138
    [Google Scholar]
  2. Directive 2001/20/EC of the european parliament and of the council of 4 april 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official J. Eur. Commun. 2001 L121 34 44
    [Google Scholar]
  3. Gefenas E. Cekanauskaite A. Lekstutiene J. Lukaseviciene V. Application challenges of the new EU clinical trials regulation. Eur. J. Clin. Pharmacol. 2017 73 7 795 798 10.1007/s00228‑017‑2267‑6 28567502
    [Google Scholar]
  4. Scavone C. di Mauro G. Pietropaolo M. Alfano R. Berrino L. Rossi F. Tomino C. Capuano A. The European clinical trials regulation (No 536/2014): Changes and challenges. Expert Rev. Clin. Pharmacol. 2019 12 11 1027 1032 10.1080/17512433.2019.1680282 31608706
    [Google Scholar]
  5. Tenti E. Simonetti G. Bochicchio M.T. Martinelli G. Main changes in european clinical trials regulation (No 536/2014). Contemp. Clin. Trials Commun. 2018 11 99 101 10.1016/j.conctc.2018.05.014 30003173
    [Google Scholar]
  6. Regulation (EU) No 536/2014 Of The European Parliament And Of The Council Of 16 April 2014 On Clinical Trials In Medicinal Products For Human Use And Repealing Directive 2001/20/EC. Official J. Eur. Commun. 2014 L158 1 76
    [Google Scholar]
  7. Flear M.L. The EU clinical trials regulation: Key priorities, purposes and aims and the implications for public health. J. Med. Ethics 2016 42 3 192 198 10.1136/medethics‑2015‑103258 26831742
    [Google Scholar]
  8. Westra A.E. Bos W. Cohen A.F. New EU clinical trials regulation. BMJ 2014 348 jun05 6 g3710 10.1136/bmj.g3710 24904029
    [Google Scholar]
  9. The EU Clinical Trials Regulation—main changes and challenges. Available from: http://www.cromsource.com/wpcontent/uploads/2015/02/The-EU-Clinical-Trials-Regulation-Main-Changes-and-Challenges.pdf (Accessed Jul 08, 2024).
  10. Hartmann M. Impact assessment of the european clinical trials directive: A longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries. Trials 2012 13 1 53 10.1186/1745‑6215‑13‑53 22540886
    [Google Scholar]
  11. Auxiliary Medicinal Products in Clinical Trials Auxiliary medicinal products in clinical trials, recommendations of the expert group on clinical trials for the implementation of regulation (EU) No 536/2014 on clinical trials on medicinal products for human use. 2014 Available from: https://health.ec.europa.eu/system/files/2017-08/2017_06_28_recommendation_on_axmps_0.pdf (Accessed Jul 05, 2024).
  12. Petrini C. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use: An overview. Ann. Ist. Super. Sanita 2014 50 4 317 321 25522070
    [Google Scholar]
  13. Clinical Research – Changes arising from the new EU Regulation No. 536/2014. 2014 Available from: https://www.inamed-cro.com/uploads/pics/Clinical_Research_-_Changes_by_new_EU_Regulation_536-2014.pdf (Accessed Jul 08, 2024).
  14. Clinical trials in the European Union (CTIS). Available from: https://euclinicaltrials.eu/ (Accessed Jul 05, 2024).
  15. Zemła-Pacud Ż. Lenarczyk G. Clinical trial data transparency in the EU: Is the new clinical trials regulation a game-changer? IIC Int. Rev. Ind. Prop. Copyr. Law 2023 54 5 732 763 10.1007/s40319‑023‑01329‑4 37215361
    [Google Scholar]
/content/journals/cds/10.2174/0115748863329287250411114336
Loading
Safety Reporting for Auxiliary Medicinal Products in the Sibeprenlimab Phase-III Study According to the New European Union (536/2014) CT Regulation
Bentham Science Publishers ; https://doi.org/10.2174/0115748863329287250411114336
/content/journals/cds/10.2174/0115748863329287250411114336
/content/journals/cds/10.2174/0115748863329287250411114336
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: auxiliary medicinal products ; angiotensin-converting enzyme inhibitors ; concomitant medications ; immediately reportable event form ; sibeprenlimab ; angiotensin receptor blockers ; Adverse event electronic case report form

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test